

Adalimumab biosimilar HADLIMA™ (adalimumab-bwwd) Added to the Medi-Cal Rx Contract Drugs List on March 1, 2024 March 8, 2024

Background

The purpose of this alert is to inform pharmacy providers and prescribers that HADLIMA™ (adalimumab-bwwd) injection was added to the <u>Medi-Cal Rx Contract Drugs List</u> (CDL).

What Pharmacy Providers and Prescribers Need to Know

Effective March 1, 2024, HADLIMA no longer requires a prior authorization (PA) request when Code I restrictions are met.

In addition, HUMIRA® (adalimumab) is still available on the CDL and is reimbursable without a PA request subject to Code I restrictions.

Pharmacy providers and prescribers are encouraged to refer to the CDL for coverage details.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.